Al's Comment:

 The concept is to try to make currently available immunotherapy drugs work better by changing the tumor microenvironment to enable the immunotherapies to work better.   This article is about good results in head and neck cancer, but they approached us about funding research into using this drug for recurrent high grade gliomas and we were so impressed that we quickly awarded them a $100,000 grant to get the clinical trial going!  As a matter of fact, one of our medical advisory board members who reviewed the grant application liked it so much, he volunteered to participate in the trial!


Posted on: 05/31/2022

PRESENTATION AT ASCO MEETING TO SHOW ENHANCED TUMOR BREAKDOWN BY COMBINING APG-157 WITH IMMUNO-ONCOLOGY DRUGS

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!